Abstract：
UNASSIGNED: Lung cancer remains an important cause of cancer-related mortality in Singapore, with a greater proportion of non-smokers diagnosed with non-small cell lung cancer (NSCLC) in the past 2 decades. The higher prevalence of targetable genomic alterations in lung cancer diagnosed in Singapore compared with countries in the West, as well as the expanding therapeutic landscape for NSCLC in the era of precision medicine, are both factors that underscore the importance of efficient and effective molecular profiling.
UNASSIGNED: This article provides consensus recommendations for biomarker testing for early-stage to advanced NSCLC. These recommendations are made from a multidisciplinary group of lung cancer experts in Singapore with the aim of improving patient care and long-term outcomes.
UNASSIGNED: The recommendations address the considerations in both the advanced and early-stage settings, and take into account challenges in the implementation of biomarker testing as well as the limitations of available data. Biomarker testing for both tumour tissue and liquid biopsy are discussed.
UNASSIGNED: This consensus statement discusses the approaches and challenges of integrating molecular testing into clinical practice for patients with early- to late-stage NSCLC, and provides practical recommendations for biomarker testing for NSCLC patients in Singapore.
UNASSIGNED: This article provides consensus recommendations for biomarker testing for early-stage to advanced NSCLC. These recommendations are made from a multidisciplinary group of lung cancer experts in Singapore with the aim of improving patient care and long-term outcomes.
UNASSIGNED: The recommendations address the considerations in both the advanced and early-stage settings, and take into account challenges in the implementation of biomarker testing as well as the limitations of available data. Biomarker testing for both tumour tissue and liquid biopsy are discussed.
UNASSIGNED: This consensus statement discusses the approaches and challenges of integrating molecular testing into clinical practice for patients with early- to late-stage NSCLC, and provides practical recommendations for biomarker testing for NSCLC patients in Singapore.
摘要：
■肺癌仍然是新加坡癌症相关死亡的重要原因，在过去的20年中，被诊断为非小细胞肺癌（NSCLC）的非吸烟者比例更高。与西方国家相比，新加坡诊断的肺癌中可靶向基因组改变的患病率更高，以及精准医学时代非小细胞肺癌不断扩大的治疗前景，这两个因素都强调了高效和有效的分子谱分析的重要性。
■本文为晚期非小细胞肺癌早期生物标志物检测提供了共识建议。这些建议是由新加坡的一个多学科肺癌专家小组提出的，目的是改善患者护理和长期预后。
■这些建议解决了高级和早期设置中的注意事项，并考虑到生物标志物测试实施中的挑战以及可用数据的局限性。讨论了肿瘤组织和液体活检的生物标志物测试。
本共识声明讨论了将分子检测纳入早期至晚期NSCLC患者临床实践的方法和挑战。并为新加坡NSCLC患者的生物标志物检测提供实用建议。
■本文为晚期非小细胞肺癌早期生物标志物检测提供了共识建议。这些建议是由新加坡的一个多学科肺癌专家小组提出的，目的是改善患者护理和长期预后。
■这些建议解决了高级和早期设置中的注意事项，并考虑到生物标志物测试实施中的挑战以及可用数据的局限性。讨论了肿瘤组织和液体活检的生物标志物测试。
本共识声明讨论了将分子检测纳入早期至晚期NSCLC患者临床实践的方法和挑战。并为新加坡NSCLC患者的生物标志物检测提供实用建议。
